NCT07063030View on ClinicalTrials.gov

A Study of LX107 Gene Therapy in AIPL1-IRD Patients

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Retinal Dystrophy
Interventions
GENETIC

LX107 Injection

Subjects will receive subretinal injection of LX107 on Day 0.

Sponsors
All Listed Sponsors
collaborator

Innostellar Biotherapeutics Co.,Ltd

INDUSTRY

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER